1. An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial. Issue 10375 (11th February 2023) Authors: Aygören-Pürsün, Emel; Zanichelli, Andrea; Cohn, Danny M; Cancian, Mauro; Hakl, Roman; Kinaciyan, Tamar; Magerl, Markus; Martinez-Saguer, Inmaculada; Stobiecki, Marcin; Farkas, Henriette; Kiani-Alikhan, Sorena; Grivcheva-Panovska, Vesna; Bernstein, Jonathan A; Li, H Henry; Longhurst, Hilary J; Aud... Journal: Lancet Issue: Volume 401:Issue 10375(2023) Page Start: 458 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Issue 10382 (1st April 2023) Authors: Craig, Timothy J; Reshef, Avner; Li, H Henry; Jacobs, Joshua S; Bernstein, Jonathan A; Farkas, Henriette; Yang, William H; Stroes, Erik S G; Ohsawa, Isao; Tachdjian, Raffi; Manning, Michael E; Lumry, William R; Saguer, Inmaculada Martinez; Aygören-Pürsün, Emel; Ritchie, Bruce; Sussman, Gordon L; ... Journal: Lancet Issue: Volume 401:Issue 10382(2023) Page Start: 1079 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial. Issue 8 (August 2020) Authors: Smith, Jaclyn A; Kitt, Michael M; Morice, Alyn H; Birring, Surinder S; McGarvey, Lorcan P; Sher, Mandel R; Li, Yu-Ping; Wu, Wen-Chi; Xu, Zhi Jin; Muccino, David R; Ford, Anthony P; Smith, Jaclyn; McGarvey, Lorcan; Birring, Surinder; Hull, James; Carr, Warner W; Goldsobel, Alan B; Gross, Gary N; H... Journal: Lancet Issue: Volume 8:Issue 8(2020) Page Start: 775 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial. Issue 10328 (5th March 2022) Authors: Craig, Timothy; Magerl, Markus; Levy, Donald S; Reshef, Avner; Lumry, William R; Martinez-Saguer, Inmaculada; Jacobs, Joshua S; Yang, William H; Ritchie, Bruce; Aygören-Pürsün, Emel; Keith, Paul K; Busse, Paula; Feuersenger, Henrike; Pawaskar, Dipti; Jacobs, Iris; Pragst, Ingo; Doyle, Mittie K Journal: Lancet Issue: Volume 399:Issue 10328(2022) Page Start: 945 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗